ArticleChemistry & biodiversity2026
Integrated Network Pharmacology, Molecular Docking, and Analysis of Active Constituents of Symplocos sumuntia Along With Their Antioxidative Activity.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Inflammation and oxidative stress are closely linked pathological processes, characterized by the excessive generation of reactive oxygen species, which activate redox-sensitive transcription factors, initiating a cascade of pro-inflammatory cytokine release that sustains cellular and tissue damage. This study examined two bioactive compounds derived from Symplocos sumuntia Buch-Ham. ex D Don for their anti-inflammatory properties. Network pharmacology analysis proposed RELA, NFKBIA, and PTGS2 as critical molecular targets, suggesting the suppression of pro-inflammatory cytokines through the NF-κB pathway. Phytochemical profiling showed that the crude extract and ETOAc fraction contained high phenolic compounds. Additionally, in vitro and in silico studies further substantiated the antioxidant properties of this plant. These findings highlight the dual anti-inflammatory and antioxidant properties of S. sumuntia, affirming its potential as a natural therapeutic candidate for inflammatory disorders. A validated HPLC-MS method was established to qualify active ingredients, which made utilization of the quality of S. sumuntia-based products on the market by controlling the content of these active constituents. Our study characterized the anti-inflammatory potentials of this plant through assessing the anti-inflammatory mechanisms of its active ingredients and highlighted that this plant might be a promising candidate for the development of anti-inflammatory and antioxidant products.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.